Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors

CAR-T therapy in solid tumors is rapidly evolving owing to the explosion of new CAR constructs, target antigens, and cellular engineering technologies. We highlighted only some of the advancements shaping this landscape. New CAR formats including CAR-NKs,132 CAR-macrophages,133 and allogeneic CAR-Ts134 may provide new opportu-nities for clinical impact. In many disease sites, the number of ongoing clinical trials greatly outnumbers those with reported results. As these trials read out over the next several years, our understanding of the impact of CAR-Ts in solid tumors will greatly expand. Our hope is that these efforts will lead to several candidate CAR-Ts for later-stage clinical testing, advancing towards the goal of achieving an approved CAR-T therapy for widespread clinical use in solid tumors.